A kind of medicine for treating advanced non-small cell lung cancer and preparation method thereof

Abstract

The invention discloses a medicine for treating advanced non-small-cell lung cancer and a preparation method of the medicine. The medicine for treating advanced non-small-cell lung cancer is prepared from raw materials in parts by weight as follows: 20-40 parts of hedyotis diffusa, 20-40 parts of scutellaria barbata, 20-40 parts of herba houttuyniae, 10-20 parts of dried tangerine peel, 20-30 parts of fructus trichosanthis, 10-20 parts of semen coicis, 20-30 parts of semen lepidii, 10-20 parts of radix scutellariae, 10-20 parts of rhizoma anemarrhenae, 10-20 parts of semen armeniacae amarae, 10-20 parts of bulbus fritillaria thunbergii, 20-30 parts of carapax trionycis, 10-20 parts of prunella vulgaris, 20-40 parts of radix astragali, 10-20 parts of codonopsis pilosula, 10-20 parts of rhizoma phragmitis, 10-20 parts of semen persicae, 10-15 parts of fructus perillae and 5-10 parts of radix glycyrrhizae preparata. The medicine has the effects of clearing heat, removing toxins, reducing phlegm, removing blood stasis, tonifying qi and nourishing yin and has functions of resisting tumor, relieving cough, eliminating phlegm and enhancing body immunity. The medicine capsules can relieve symptoms of patients, have exact curative effect and can prolong lifetime of the patients and improve the life quality.

Description

technical field [0001] The invention belongs to a traditional Chinese medicine preparation and a preparation method thereof, in particular to a medicine for treating advanced non-small cell lung cancer and a preparation method thereof. Background technique [0002] The incidence of lung cancer ranks first in the global cancer. The incidence rate of lung cancer in my country is 46.08 per 100,000 people, and the mortality rate is obviously on the rise. It has become the first cause of cancer death. Non-small cell lung cancer is a type of lung cancer, which includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Compared with small cell carcinoma, the growth and division of its cancer cells are slower, and the diffusion and metastasis are relatively late. Non-small cell lung cancer accounts for about 80-85% of the total lung cancer cases. Because the patients have no obvious symptoms in the early stage, 75% of the patients are already in the advanced stage ...

AI Technical Summary

Problems solved by technology

Non-small cell lung cancer accounts for about 80-85% of the total lung cancer cases. Because the patients have no obvious symptoms in the early stage, 75% of the patients are already in the advanced stage when they go to the doctor. The 5-year survival rate is less than 2%, and the prognosis is extremely poor.

Chemoradiotherapy is the first choice in the treatment of advanced non-small cell lung cancer, but it is only for patients with better quality of life scores, and it is contraindicated for elderly patients, poor quality of life, cardiopulmonary and renal insufficiency, and patients who cannot tolerate it

Targeted therapy is only effective for patients with gene mutations, and immunotherapy is expensive, and its efficacy remains to be evaluated

Images